Összes fotó(1)
Fontos dokumentumok
SHP001
MISSION® Lentiviral Packaging Mix
Production of replication incompetent viral particles
Szinonimák:
Lentiviral Packaging, Lentiviral Packaging Kit
Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)
About This Item
UNSPSC kód:
41106609
NACRES:
NA.51
Javasolt termékek
Related Categories
Általános leírás
The MISSION® shRNA product line is centered on a transfer vector-based RNAi library against annotated mouse and human genes that can be used in conjunction with this Lentiviral Packaging Mix. In this packaging system, the pseudo-typing with VSV-G broadens the viral tropism associated with the virus. Therefore, these lentiviral particles can efficiently deliver the transfer sequence of interest to a wide variety of cell types, including primary and non-dividing cells.
The MISSION® Lentiviral Packaging Mix is an optimized formulation of two plasmids expressing the key HIV packaging genes and a heterologous viral envelope gene.
Lentiviral particles are generated from three main components:
The Lentiviral Packaging Mix contains the first two components; it is designed to be co-transfected along with a compatible lentiviral transfer vector in order to create high-titer pseudo-typed lentiviral particles used for downstream transduction applications.
The MISSION® Lentiviral Packaging Mix is an optimized formulation of two plasmids expressing the key HIV packaging genes and a heterologous viral envelope gene.
Lentiviral particles are generated from three main components:
- The packaging vector, which contains the minimal set of lentiviral genes required to generate the virion structural proteins and packaging functions.
- The vesicular stomatitis virus G-protein envelope vector, which provides the heterologous envelope for pseudotyping.
- The shRNA transfer vector, which contains the sequence of interest as well as the cis acting sequences necessary for RNA production and packaging.
The Lentiviral Packaging Mix contains the first two components; it is designed to be co-transfected along with a compatible lentiviral transfer vector in order to create high-titer pseudo-typed lentiviral particles used for downstream transduction applications.
Alkalmazás
MISSION® Lentiviral Packaging Mix has been used to incubate plasmids before addition to human embryonic kidney cells 293 expressing the large T antigen (293T cells) and to pack lentivirus into 293T cells.
Egyéb megjegyzések
Lentiviral particles are produced using a third-generation packaging system, which has many features that lead to enhanced biosafety. Recombinant lentiviruses produced with the MISSION Lentiviral Packaging Mix have not been shown to produce replication competent viral particles because of designed safety features. Users should consult and observe their own institutional guidelines before working with such viral systems.
Jogi információk
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense .
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Tárolási osztály kódja
10 - Combustible liquids
WGK
WGK 2
Lobbanási pont (F)
Not applicable
Lobbanási pont (C)
Not applicable
Válasszon a legfrissebb verziók közül:
Analitikai tanúsítványok (COA)
Lot/Batch Number
Sajnos jelenleg COA nem áll rendelkezésre ehhez a termékhez online.
Ha segítségre van szüksége, lépjen velünk kapcsolatba Vevőszolgálat
Már rendelkezik ezzel a termékkel?
Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.
Az ügyfelek ezeket is megtekintették
Wenwen Chien et al.
Journal of Cancer, 9(24), 4762-4773 (2018-12-28)
This study is an unbiased genomic screen to obtain functional targets for increased effectiveness of dasatinib in pancreatic cancer. Dasatinib, a multi-targeted tyrosine kinase inhibitor, is used in clinical trials for treatment of pancreatic cancer; however, intrinsic and acquired resistance
SNAI1-Driven Sequential EMT Changes Attributed by Selective Chromatin Enrichment of RAD21 and GRHL2.
Vignesh Sundararajan et al.
Cancers, 12(5) (2020-05-07)
Over two decades of research on cancer-associated epithelial-mesenchymal transition (EMT) led us to ascertain the occurrence of transitional intermediate states (collectively referred to as the EMT spectrum). Among the molecular factors that drive EMT, SNAI1 plays an indispensable role in
NIH Guidelines for Research Involving Recombinant DNA Molecules
N.I.H. Memorandum (2002)
Kathleen W Clancy et al.
ACS chemical biology, 12(6), 1691-1702 (2017-05-10)
Posttranslational modifications of histone tails are a key contributor to epigenetic regulation. Histone H3 Arg26 and Lys27 are both modified by multiple enzymes, and their modifications have profound effects on gene expression. Citrullination of H3R26 by PAD2 and methylation of
GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification.
Chung VY
Scientific Reports, 6 (2016)
Cikkek
MISSION shRNA reduce the expression of specific target genes by targeting the specific mRNA therefore reducing the corresponding protein expression.
When shRNA is delivered using lentiviral vectors, the sequence encoding the shRNA is integrated into the genome and the knockdown effect is passed on to daughter cells, continuing gene silencing.
Protocols
Preparation of the Lentiviral Transduction Particles Using Packaging Plasmid Mix
Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.
Lépjen kapcsolatba a szaktanácsadással